When does ixekizumab (Taltz) lose exclusivity in the US?
Taltz is protected by multiple layers of IP (not just one “exclusivity” date). The exact end date depends on which form of exclusivity is being considered (FDA marketing exclusivity vs. patent terms vs. any pediatric exclusivity adjustments), and on how long relevant patents remain enforceable for the specific claims tied to ixekizumab.
What “exclusivity” usually means for Taltz (and why dates can differ)
Drug “exclusivity” can refer to different protections with different timelines:
- Patent expiry for specific claims covering the drug/product and/or manufacturing.
- Regulatory exclusivity tied to FDA approvals (for example, new drug or related exclusivity periods).
- Pediatric exclusivity extensions, which can push out patent-expiry timelines for qualifying patents.
Because those categories do not always line up, “the” date a medicine loses exclusivity can vary depending on the legal and regulatory basis being asked about.
What happens if a company files for a biosimilar before Taltz exclusivity ends?
If a biosimilar applicant files under the abbreviated pathway while Taltz is still within protected periods, the applicant can usually proceed with development and may be able to submit data, but approval/launch is often blocked until the relevant exclusivity or patent barriers expire or are cleared through settlement/litigation.
Which details are needed to give the exact ixekizumab exclusivity/expiry date
To state a precise “lost of exclusivity” date for ixekizumab, you typically need at least:
- The country/region (US vs EU vs UK vs elsewhere)
- Whether you mean patent expiry, FDA exclusivity, or both
- The specific biosimilar/payer context (sometimes insurers ask about when a biosimilar can be marketed)
If you tell me the geography (US or EU) and whether you want patent expiry or FDA exclusivity, I can narrow the answer to the specific timeline.
If you meant EU/UK market exclusivity instead of US
EU countries generally rely on different legal frameworks (including marketing protection and data/exclusivity rules under EU law). The “end date” can differ from the US because the protections and calculating methods differ.
Quick clarification
Do you mean:
1) US patent expiry / biosimilar launch date for ixekizumab (Taltz), or
2) EU/UK exclusivity (marketing/data protection), or
3) FDA marketing exclusivity specifically?
Reply with the region and which type of exclusivity you mean, and I’ll give the exact end point.